HOPA is committed providing high quality education that is strongly integrated with HOPA’s core passion to support pharmacy practitioners and promote and advance Hematology/Oncology Pharmacy to optimize the care of individuals affected by cancer. HOPA strives to become the destination of choice for quality education focused on creating competent hematology/oncology pharmacists with sound domain knowledge, skills and managerial acumen.  Below is the full spectrum of education offerings – you may also sort by content area, date, delivery method, and if it offers BCOP recertification credit.

Targeting FLT3: an Update in the Management of FLT3-Mutated Acute Myeloid Lukemia (AML)

Originally presented at HOPA's 14th Annual Conference, March 2018.

In April 2017, the U.S. Food and Drug Administration approved the first tyrosine kinase inhibitor for the treatment of patients diagnosed with AML. The approval of midostaurin marks the beginning of targeted therapy development for this difficult-to-treat disease. Three other FLT3 inhibitors are currently in phase 2 trials for AML and show promising efficacy, which may dramatically change the treatment paradigm for this disease. This session will provide an overview of FLT3-mutated AML, including currently available treatment, first- and second-generation inhibitors, mechanisms of resistance, and future directions. The session is directed to the advanced practitioner.


Amanda Seddon, PharmD BCOP BCPS

Activity type

Patient Management & Therapeutics

Accreditation Statement

logo acpe

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.

This activity has been approved for .1 CEU

This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.

Release Date: September 26, 2018

Expiration Date: March 22, 2021

Member: $25

Non-Member: $35

Purchase Now